Stammdaten
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Unternehmen & Branche
| Name | ZyVersa Therapeutics, Inc. |
|---|---|
| Ticker | ZVSA |
| CIK | 0001859007 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,7 Mio. USD |
| Beta | 0,70 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -24,952,378 | -4.18 | 347,901 | -12,386,786 | |
| 2025-09-30 | 10-Q | -19,805,559 | -2.56 | 1,040,260 | -11,725,567 | |
| 2025-06-30 | 10-Q | -2,211,317 | -0.46 | 19,641,111 | 6,099,774 | |
| 2025-03-31 | 10-Q | -2,256,930 | -0.73 | 20,985,541 | 8,130,350 | |
| 2024-12-31 | 10-K | -9,413,435 | -8.48 | 20,599,414 | 8,516,447 | |
| 2024-09-30 | 10-Q | -2,401,256 | -2.43 | 19,423,924 | 7,027,300 | |
| 2024-06-30 | 10-Q | -2,763,743 | -3.31 | 19,469,504 | 8,620,055 | |
| 2024-03-31 | 10-Q | -2,826,737 | -4.53 | 21,650,764 | 11,223,134 | |
| 2023-12-31 | 10-K | -98,297,946 | -###.## | 22,114,284 | 11,074,598 | |
| 2023-09-30 | 10-Q | -2,902,403 | -30.18 | 32,852,009 | 19,703,659 | |
| 2023-06-30 | 10-Q | -78,513,093 | -###.## | 31,987,793 | 20,061,642 | |
| 2023-03-31 | 10-Q | -3,543,950 | -135.88 | 114,953,702 | 97,098,365 | |
| 2022-12-31 | 10-K | -75,018 | -0.29 | 118,506,271 | 99,662,997 | |
| 2022-12-12 | 10-K | -14,047,607 | -0.99 | 99,681,682 | ||
| 2022-09-30 | 10-Q | -679,087 | 79,397,236 | -4,158,937 | ||
| 2022-06-30 | 10-Q | -393,639 | 79,226,647 | -3,372,123 | ||
| 2022-03-31 | 10-Q | -720,006 | 79,673,282 | -2,978,484 | ||
| 2021-12-31 | 10-K | -240,700 | 77,143,357 | -2,258,478 | ||
| 2021-09-30 | 10-Q | -174 | -1,402 | |||
| 2021-06-30 | 10-Q | -789 | -1,228 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.